Cancer Treatment Reviews
Volume 29 , Pages 41-48 , May 2003

Clinical update: proteasome inhibitors in solid tumors

  • Heinz-Josef Lenz

      Affiliations

    • Corresponding Author InformationCorrespondence to: Heinz-Josef Lenz, MD, FACP, USC/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Ste 3456, Los Angeles, CA 90033, USA. Tel.: 1-323-865-3967; Fax: 1-323-865-0061

References 

  1. Adams J, Palombella VJ, Sausville EA, et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615–2622
  2. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000;18(2):109–121
  3. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996;56(11):2649–2654
  4. Read MA, Neish AS, Luscinskas FW, et al.  The proteasome pathway is required for cytokine-induced endothelial- -leukocyte adhesion molecule expression. Immunity. 1995;2(5):493–506
  5. Sunwoo JB, Chen Z, Dong G, et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001;7(5):1419–1428
  6. Teicher BA, Ara G, Herbst R, et al.  The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 1999;5(9):2638–2645
  7. Cusack JC, Liu R, Houston M, et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61(9):3535–3540
  8. Shah SA, Potter MW, McDade TP, et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 2001;82(1):110–122
  9. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 2001;100(1):11–17
  10. Pink M, Pien CS, Worland P, et al.  PS-341 enhances chemotherapeutic effect in human xenograft models. Proc. Am. Assoc. Cancer Res. 2002;43:158
  11. Aghajanian C, Soignet S, Dizon DS, et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002;8(8):2505–2511
  12. Papandreou C, Daliani D, Millikan RE, et al. Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (Pts) with advanced malignancies. In: Proceedings of the American Society of Clinical Oncology—37th Annual Meeting, vol. 20; 2001. p. 86a
  13. Hamilton AL, Eder J, Pavlick AC, et al. PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. In: Proceedings of the American Society of Clinical Oncology—37th Annual Meeting, vol. 20; 2001. p. 85a
  14. Clark JW, Ryan D, Dees C, et al. Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors. In: Proceedings of the American Society of Clinical Oncology—38th Annual Meeting, vol. 21; 2002. p. 93a
  15. Ryan DP, Eder JP, Winklemann J, et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. In: Proceedings of the American Society of Clinical Oncology—38th Annual Meeting, vol. 21; 2002. p. 95a
  16. Iqbal S, Lenz H-J, Groshen S, et al. Phase I study of PS-341 in combination with 5-FU/LV in solid tumors. Proceedings of the American Society of Clinical Oncology—38th Annual Meeting, vol. 21; 2002. p. 93a
  17. Pagano M, Tam SW, Theodoras AM, et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269(5224):682–685
  18. Yatabe Y, Masuda A, Koshikawa T, et al.  p27KIP1 in human lung cancers:differential changes in small cell and non-small cell carcinomas. Cancer Res. 1998;58(5):1042–1047
  19. Esposito V, Baldi A, De Luca A, et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57(16):3381–3385
  20. Kamat AM, Karashima T, Dinney CP, McConkey DJ. The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. Proc. Am. Assoc. Cancer Res. 2002;43:157
  21. Thornton JD, Liu, R, Orlowski, RZ, et al. Doxorubicin-induced NF-kappaB activation in breast cancer is overcome by proteasome inhibition, resulting in enhanced tumoricidal response to treatment. Presented at the 87th Annual Clinical Congress of the American College of Surgeons, New Orleans, LA, October 7-12; 2001
  22. Russo SM, Tepper JE, Baldwin AS, et al.  Enhancement of radiosensitivity by proteasome inhibition:implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 2001;50(1):183–193
  23. Chen Z, Malhotra PS, Gill R, et al.  Identification of sensitive and resistant head and neck squamous cell carcinoma lines to PS-341, a novel anti-cancer agent inhibiting proteasome dependent activation of NF-κB. Proc. Am. Assoc. Cancer Res. 2002;43:158
  24. Ling YH, Jiang J-D, Liebes L, et al.  Molecular mechanisms of proteasome inhibitor PS-341-induced G2/M phase arrest and apoptosis in human non-small cell lung cancer H460 cells. Proc. Am. Assoc. Cancer Res. 2002;43:665
  25. Gumerlock PH, Moisan LP, Lau AH, et al.  Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increases response in non-small cell lung carcinoma (NSCLC). Clin. Cancer Res. 2001;7(11):157
  26. Frankel A, Man S, Elliott P, et al.  Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000;6(9):3719–3728
  27. Nawrocki ST, McConkey DJ. The proteasome inhibitor, PS-341, inhibits the growth of pancreatic cancer cells in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 2002;43:159
  28. Sclabas GM, Dong QG, Fujioka S, et al.  Drug-elicited apoptosis in pancreatic tumor cells: the role of different complexes between IκB and NF-κB. Proc. Am. Assoc. Cancer Res. 2002;43:882
  29. Pervan M, Pajonk F, Sun JR, et al.  Molecular pathways that modify tumor radiation response. Am. J. Clin. Oncol. 2001;24(5):481–485
  30. Williams SA, Papandreou C, McConkey D. Preclinical effects of proteasome inhibitor PS-341 in combination chemotherapy for prostate cancer. In: Proceedings of the American Society of Clinical Oncology—37th Annual Meeting, vol. 20; 2001. p. 169b

PII: S0305-7372(03)00082-3

doi: 10.1016/S0305-7372(03)00082-3

Cancer Treatment Reviews
Volume 29 , Pages 41-48 , May 2003

Article Tools

* Image Usage & Resolution